Fusion-Abs
First-in-Class Fusion-Abs
Fusion Antibodies
Category
Fusion
Antibody
Pipeline
IDC331
Indication
Solid Tumors
Development Stage
- Lead optimization 5%
Category
Fusion
Antibody
Pipeline
IDC332
Indication
Solid Tumors
Development Stage
- Lead optimization 5%
Improving Accessibility & Affordability for Enhancing Patient Access to Medications
Prestige Biopharma strives to enhance drug accessibility for patients’ unmet needs through the development of novel antibody therapeutics and biosimilars. Our portfolio of 12 novel antibody pipelines represents our mission and efforts to fight serious cancers like pancreatic cancer for improving patients’ lives.
Our groundbreaking accomplishments